Therefore, currently available data suggest that the addition of 80 mg gilteritinib daily to VEN alone or AZA/DEC + VEN to earlier treatment phases leads to superior outcomes in FLT3-mutated AML patients. This evidence concerns the gene FLT3 and acute myeloid leukemia.